IBA and ScandiDos form strategic alliance to increase access to safe radiotherapy

September 1, 2022 — IBA SA, a leader in particle accelerator technology and a leader in dosimetry quality assurance solutions, and ScandiDos AB (SDOS.ST), a technology leader in advanced radiotherapy quality assurance, announced that they have formed a strategic alliance to radiotherapy dosimetry solutions. The collaboration will allow both companies to work together on product development, marketing and product distribution in selected markets, for the quality assurance of radiation therapy patients. The details of the collaboration will be worked out jointly by the parties in the coming months.

IBA Dosimetry and ScandiDos have entered into this collaboration as part of their shared vision of a complete radiotherapy quality assurance solution. By combining the two companies’ portfolios, IBA Dosimetry and ScandiDos can accomplish this vision, offering an ever-expanding product suite that provides a cohesive solution for all aspects of radiotherapy quality assurance.

Under the terms of the agreement, IBA will purchase the entire share issue (4,150,000 shares) carried out by ScandiDos on August 30 at a price of SEK 3.00, corresponding to an 8% premium on the average Last 12 months of the company’s listing on the Stockholm Stock Exchange. Sotck exchange. Following the transaction, IBA will hold 9.1% of ScandiDos AB’s share capital.

Jean-Marc Bothy, President of IBA Dosimetry, said: “This is an important step in our ongoing industrial consolidation strategy. We are proud that ScandiDos chose us as their partner for their expansion. For years we have been impressed with the quality of the ScandiDos patient quality assurance product portfolio and believe it is complementary to our expanding hardware and software offering. The combination of the two companies’ product offerings will provide a unique level of quality, simplicity and versatility to the medical physics community, enabling them to deliver all the benefits of radiation therapy, with improved safety profiles to patients with of cancer all over the world.

Gustaf Piehl, CEO of ScandiDos AB, added: “Sharing a similar, long-term view of the radiotherapy quality assurance market has been fundamental to building this alliance. By working with IBA, a leading industry partner, ScandiDos will reach more customers worldwide and help make radiotherapy even safer than it is today. This strategic collaboration will also allow ScandiDos to retain its independence to further develop the business while relying on IBA’s strong organizational capabilities.

For more information: www.iba-worldwide.com

Comments are closed.